NasdaqGS:REGNBiotechs
Is Dupixent’s First AFRS Approval Altering The Investment Case For Regeneron Pharmaceuticals (REGN)?
Regeneron Pharmaceuticals and Sanofi recently received U.S. FDA approval for Dupixent to treat allergic fungal rhinosinusitis (AFRS) in adults and children aged 6 and older with a history of sino-nasal surgery, following a Priority Review supported by a Phase 3 trial showing marked improvements in sinus disease and symptoms.
This ninth U.S. approval for Dupixent broadens its role in type 2 inflammatory diseases and introduces the first medicine specifically approved for AFRS, potentially...